" class="no-js "lang="en-US"> Mark Nelson - Medtech Alert
Tuesday, April 16, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Mark Nelson

Mark Nelson

About Mark Nelson

Experienced Chief Executive Officer with a demonstrated history of working in the medical practice industry. Strong business development professional skilled in Management, Healthcare Management, Pharmaceutical Industry, Healthcare, and Leadership.

Related Story

Industry News

 Quality Cancer Care Alliance (QCCA) and ConcertAI Partner on Novel Digital Clinical Trial Solutions

Quality Cancer Care Alliance (QCCA) and ConcertAI Partner on Novel Digital Clinical Trial Solutions, Accelerating Patient Access to Clinical Trials

August 31 2021

ConcertAI, LLC (ConcertAI), a market leader for Real-World Evidence (RWE) and enterprise AI Software-as-a-Service (SaaS) […]